MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy
MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy
复制标题
DOI：
10.1002/cncr.23130
复制
发表时间：
2008-01-01
期刊：
影响因子：
6.2
通讯作者：
Su, Min Ying
中科院分区：
文献类型：
--
作者：
Chen, Jeon Hor;Feig, Lyon;Su, Min Ying
背景资料。本研究探讨磁共振成像(MRI)对HER-2阳性和阴性乳腺癌患者接受新辅助化疗(NAC)后病理完全缓解和肿瘤残留的评估作用。方法：51例患者，其中HER-2阳性25例，HFR-2阴性26例。在NAG油最终MRI的基础上，在进行系列MRI检查之前、期间和之后，确定其反应为临床完全缓解([CCR]，无强化)、可能的CCR(残余强化等于或小于腺体组织)或残留肿瘤。所有接受手术的患者的病理结果分为：1)无残留癌，2)无残留浸润癌但有导管原位癌(DCIS)，或3)残留浸润癌。病理完全反应(PCR)定义为非侵袭性癌。结果：MRI显示35例患者(35/51，69%)临床完全缓解，包括CCR和可能的CCR。MRI正确诊断PCR26例(26/35，74%)，其中FIER-2阳性组18例(95%)，HER-2阴性组8例(50%)(P
BACKGROUND. This Study investigated the role of magnetic resonance imaging (MRI) in evaluation of pathologically complete response and residual tumors in patients who were receiving neoadjuvant chemotherapy (NAC) for both positive and negative HER-2 breast cancer.METHODS. Fifty-one individuals, comprised of 25 HER-2 positive and 26 HFR-2 negative patients, were included in the study. Serial MRI studies were acquired before, during, and after NAG Oil the basis of the final MRI, response was determined to be a clinically complete response ([CCR], no enhancement), probable CCR (residual enhancement equal to or less than that of glandular tissue), or residual tumor. All patients received surgery Pathological outcomes were categorized as 1) no residual cancer, 2) no residual invasive cancer but ductal carcinoma in Situ (DCIS) present, or 3) residual invasive cancer. The pathologically complete response (pCR) was defined as no invasive cancer.RESULTS. Complete clinical response as seen through MRI, including CCR and probable CCR, was identified in 35 (35 of 51, 69%) patients. MRI correctly diagnosed pCR in 26 (26 of 35, 74%) patients, including 18 of 19 (95%) patients ill the FIER-2 positive group and 8 of 16 (50%) patients in the HER-2 negative group (P